Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Lentivirus-mediated RNA interference of tripartite motif 68 inhibits the proliferation of colorectal cancer cell lines SW1116 and HCT116 in vitro.

Tan Z, Liu X, Yu E, Wang H, Tang L, Wang H, Fu C.

Oncol Lett. 2017 Apr;13(4):2649-2655. doi: 10.3892/ol.2017.5787. Epub 2017 Feb 28.

2.

Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers.

Panaccione A, Guo Y, Yarbrough WG, Ivanov SV.

Clin Breast Cancer. 2017 Jul;17(4):298-306.e7. doi: 10.1016/j.clbc.2017.01.007. Epub 2017 Jan 27.

PMID:
28216417
3.

Growth hormone is permissive for neoplastic colon growth.

Chesnokova V, Zonis S, Zhou C, Recouvreux MV, Ben-Shlomo A, Araki T, Barrett R, Workman M, Wawrowsky K, Ljubimov VA, Uhart M, Melmed S.

Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):E3250-9. doi: 10.1073/pnas.1600561113. Epub 2016 May 25. Erratum in: Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5251.

4.

Identification of nasopharyngeal carcinoma metastasis-related biomarkers by iTRAQ combined with 2D-LC-MS/MS.

Chen Z, Long L, Wang K, Cui F, Zhu L, Tao Y, Wu Q, Xiang M, Liang Y, Qiu S, Xiao Z, Yi B.

Oncotarget. 2016 Jun 7;7(23):34022-37. doi: 10.18632/oncotarget.9067.

5.

Tripartite motif-containing 29 as a novel biomarker in non-small cell lung cancer.

Song X, Fu C, Yang X, Sun D, Zhang X, Zhang J.

Oncol Lett. 2015 Oct;10(4):2283-2288. Epub 2015 Aug 19.

6.

ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms.

Palmbos PL, Wang L, Yang H, Wang Y, Leflein J, Ahmet ML, Wilkinson JE, Kumar-Sinha C, Ney GM, Tomlins SA, Daignault S, Kunju LP, Wu XR, Lotan Y, Liebert M, Ljungman ME, Simeone DM.

Cancer Res. 2015 Dec 1;75(23):5155-66. doi: 10.1158/0008-5472.CAN-15-0603. Epub 2015 Oct 15.

7.

ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase.

Yang H, Palmbos PL, Wang L, Kim EH, Ney GM, Liu C, Prasad J, Misek DE, Yu X, Ljungman M, Simeone DM.

J Biol Chem. 2015 Nov 6;290(45):27146-57. doi: 10.1074/jbc.M115.665489. Epub 2015 Sep 17.

8.

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis.

Hiraki M, Hwang SY, Cao S, Ramadhar TR, Byun S, Yoon KW, Lee JH, Chu K, Gurkar AU, Kolev V, Zhang J, Namba T, Murphy ME, Newman DJ, Mandinova A, Clardy J, Lee SW.

Chem Biol. 2015 Sep 17;22(9):1206-16. doi: 10.1016/j.chembiol.2015.07.016. Epub 2015 Aug 27.

9.
10.

TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185.

Qiu F, Xiong JP, Deng J, Xiang XJ.

Int J Clin Exp Pathol. 2015 May 1;8(5):5053-61. eCollection 2015.

11.

ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis.

Wang L, Yang H, Abel EV, Ney GM, Palmbos PL, Bednar F, Zhang Y, Leflein J, Waghray M, Owens S, Wilkinson JE, Prasad J, Ljungman M, Rhim AD, Pasca di Magliano M, Simeone DM.

Genes Dev. 2015 Jan 15;29(2):171-83. doi: 10.1101/gad.253591.114.

12.

Proteomic analysis of oral cavity squamous cell carcinoma specimens identifies patient outcome-associated proteins.

Harris TM, Du P, Kawachi N, Belbin TJ, Wang Y, Schlecht NF, Ow TJ, Keller CE, Childs GJ, Smith RV, Angeletti RH, Prystowsky MB, Lim J.

Arch Pathol Lab Med. 2015 Apr;139(4):494-507. doi: 10.5858/arpa.2014-0131-OA. Epub 2014 Oct 8.

13.

TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma.

Caratozzolo MF, Valletti A, Gigante M, Aiello I, Mastropasqua F, Marzano F, Ditonno P, Carrieri G, Simonnet H, D'Erchia AM, Ranieri E, Pesole G, Sbisà E, Tullo A.

Oncotarget. 2014 Sep 15;5(17):7446-57.

14.

Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes.

Kung CP, Khaku S, Jennis M, Zhou Y, Murphy ME.

Mol Cancer Res. 2015 Feb;13(2):250-62. doi: 10.1158/1541-7786.MCR-14-0385. Epub 2014 Sep 25.

15.

TRIM29 suppresses TWIST1 and invasive breast cancer behavior.

Ai L, Kim WJ, Alpay M, Tang M, Pardo CE, Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM, Brown KD.

Cancer Res. 2014 Sep 1;74(17):4875-87. doi: 10.1158/0008-5472.CAN-13-3579. Epub 2014 Jun 20.

16.

TRIM29 as a novel biomarker in pancreatic adenocarcinoma.

Sun H, Dai X, Han B.

Dis Markers. 2014;2014:317817. doi: 10.1155/2014/317817. Epub 2014 Apr 22.

17.

Tissue specific DNA methylation in normal human breast epithelium and in breast cancer.

Avraham A, Cho SS, Uhlmann R, Polak ML, Sandbank J, Karni T, Pappo I, Halperin R, Vaknin Z, Sella A, Sukumar S, Evron E.

PLoS One. 2014 Mar 20;9(3):e91805. doi: 10.1371/journal.pone.0091805. eCollection 2014.

18.

ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells.

Wang L, Yang H, Palmbos PL, Ney G, Detzler TA, Coleman D, Leflein J, Davis M, Zhang M, Tang W, Hicks JK, Helchowski CM, Prasad J, Lawrence TS, Xu L, Yu X, Canman CE, Ljungman M, Simeone DM.

Cancer Res. 2014 Mar 15;74(6):1778-88. doi: 10.1158/0008-5472.CAN-13-2289. Epub 2014 Jan 27.

19.

Ataxia-telangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NF-κB pathway.

Tang ZP, Dong QZ, Cui QZ, Papavassiliou P, Wang ED, Wang EH.

PLoS One. 2013 Jun 12;8(6):e63676. doi: 10.1371/journal.pone.0063676. Print 2013.

20.

Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage.

Ozaki T, Wu D, Sugimoto H, Nagase H, Nakagawara A.

Cell Death Dis. 2013 Apr 25;4:e610. doi: 10.1038/cddis.2013.127.

Supplemental Content

Support Center